Abiraterone Outcomes Tied to NLR
For example, men with a baseline NLR below 2.5, patients who received abiraterone had a significant 28% decreased risk of death.
For example, men with a baseline NLR below 2.5, patients who received abiraterone had a significant 28% decreased risk of death.
Incredible progress is being made in kidney cancer treatment.
Avelumab plus axitinib is associated with longer progression-free survival compared with sunitinib as first-line therapy in patients with advanced renal cell carcinoma.
As stearic acid and total fatty acid intake increased from one quintile to the next, prostate risk increased by 23% and 21%, respectively.
Patient selection and physician-patient commitment to careful follow-up surveillance are key.
Findings from a large contemporary cohort of men on active surveillance for prostate cancer shows that disease characteristics, not socioeconomic factors, are driving prostate cancer management.
At the time of diagnosis of renal cell carcinoma, blacks had 33% lower odds of regional disease compared with whites, a new study found.
The professional obligation to promote the health and wellbeing of the members of society is central to the legitimacy and integrity of the profession.
A study of new dialysis patients showed that home hemodialysis was associated with a 23% decreased risk of death at 1 year compared with in-center hemodialysis.
A polymer that binds to hydrochloric acid in the GI tract and does not enter the systemic circulation significantly improved serum bicarbonate levels compared with placebo.